Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1601-1604

  Calin, Ruxandra ^a   Paris, Luc ^a,b   Simon, Anne ^a   Peytavin, Gilles ^c   Wirden, Marc ^a,b,d   Schneider, Luminita ^a,d   Valantin, Marc Antoine ^a,d   Tubiana, Roland ^a,d   Agher, Rachid ^a,d   Katlama, Christine ^a,b,d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY DYSFUNCTION; LIPODYSTROPHY; METABOLIC DISORDER; NEUROTOXICITY; PILOT STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84871911114     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2344     Document Type: Article

References (17)

1. Lennox JL, De Jesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796-806.
2. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimal background therapy in treatment- experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 iii trials. Clin Infect Dis 2010; 50:605-612.
3. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-1449.
4. Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 2010; 15:1045-1052.
5. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53:807-816.
6. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
7. Fätkenheuer G, Duvivier C, Rieger A, et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother 2012; 67:685-690.
8. Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9:545-559.
9. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
10. D'Ascenzo F, Cerrato E, Biondi-Zoccai G, et al. Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J 2012; 33:875-880.
11. Burger DM. Raltegravir: a review of its pharmacokinetic, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010; 6:1151-1160.
12. Anderson MS, Kakuda TN, Hanley W, et al. Minimal pharmacokinetic interaction between the HIV non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother 2008; 52:4228-4232.
13. Ménard A, Solas C, Mokthari S, et al. Etravirine-raltegravir a marked interaction in HIV-1 infected patients: about four cases. AIDS 2009; 27:869-871.
14. Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. AIDS 2010; 24:2581-2583.
15. Reliquet V, Chirouze C, Muret P, et al. Raltegravir (RAL) and nevirapine (NVP) dual therapy maintains virologic suppression in HIV-infected HAART-treated patients: 48-week results of a pilot study. 13th European AIDS Conference. 12-15 October 2011, Belgrade, Serbia. Poster PE7.3/3.
16. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697-1707.
17. Nelson M, Stellbrink HJ, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS 2011; 25:335-340.